Sign Out
Hypersensitivity to the active substance or to any of the excipients listed in Description.
Left ventricular outflow tract obstruction.
Untreated congestive cardiac failure.
Unstable angina pectoris or recent (within 1 month) myocardial infarction.
Severe hepatic impairment.
Severe renal impairment (GFR < 30 ml/min), including patients undergoing dialysis.
Co-administration with: strong inhibitors of CYP3A4 (see Interactions), cyclosporin (see Interactions), grapefruit or grapefruit juice (see Interactions).
